The effect of a balanced amino acid infusion on hepatic regeneration in rats by Anstadt, Robert Arthur
University of the Pacific 
Scholarly Commons 
University of the Pacific Theses and 
Dissertations Graduate School 
1987 
The effect of a balanced amino acid infusion on hepatic 
regeneration in rats 
Robert Arthur Anstadt 
University of the Pacific 
Follow this and additional works at: https://scholarlycommons.pacific.edu/uop_etds 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
Recommended Citation 
Anstadt, Robert Arthur. (1987). The effect of a balanced amino acid infusion on hepatic regeneration in 
rats. University of the Pacific, Thesis. https://scholarlycommons.pacific.edu/uop_etds/2134 
This Thesis is brought to you for free and open access by the Graduate School at Scholarly Commons. It has been 
accepted for inclusion in University of the Pacific Theses and Dissertations by an authorized administrator of 
Scholarly Commons. For more information, please contact mgibney@pacific.edu. 
The Effect of a Balanced Amino Acid 
Infusion on Hepatic Regeneration 
in Rats 
A Thesis 
Presented to 
the Faculty of the Graduate School 
University of the Pacific 
In Partial Fulfillment 
of the Requirements for the Degree 
Master of Science 
by 
Robert A. Anstadt 
April 1987 
.; 
I 
! 
Abstract 
The efficacy of a balanced amino acid infusion on 
recovery from temporary hepatic insufficiency and its 
effect on plasma ammonia levels in partially hepatectomized 
rats were studied. 
Polyethylene implant buttons were developed to secure 
animals to the infusion apparatus. Rats under went jugular 
vein cannulation, and 70% partial hepatectomy. Test 
solutions were continuously infused (30 ml/d). Plasma 
samples were taken through the jugular vein cannula and 
analyzed for bilirubin concentration, ammonia concentration, 
LDH activity, and GPT activity. 
LDH and bilirubin results were inconclusive. Results 
from GPT activity assays suggest that both Freamine III and 
the balanced formula provided injured hepatocytes with 
better nutrition than saline infusions and ad libitum food 
consumption. Ammonia assay results suggest that the 
balanced formula was more effective than Freamine in 
maintaining plasma ammonia levels in the normal range after 
partial hepatectomy. 
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Introduction 
Over 150 years ago it was discovered that dogs fed a 
diet free of nitrogen would die prematurely, whereas this 
early death could be prevented by adding protein to this 
diet. Dietary proteins in their native form were not really 
what was saving the animals from their early demise, however 
since proteins as such cannot be absorbed by the digestive 
tract. Proteins must be broken down into their constituent 
amino acids before intestinal absorbtion can occur. 
Of all amino acids in existence, 20 are shared by all 
living organisms. A few others are not found in proteins 
but play important physiologic roles. Some proteins also 
contain amino acids other than the 20 common ones. Amino 
acids pass through the intestine into the portal circulation 
in free form. Thus portal vein amino acid concentrations 
are much greater than systemic circulatory concentrations. 
Individual amino acids levels in the portal circulation do 
not reflect dietary protein amino acid composition since 
some endogenous amino acids from proteins secreted into the 
digestive tract are also absorbed. The amount of endogenous 
protein reabsorbed in the intestine has been estimated to be 
from 140 to 350 g/d.l,2 
Plasma amino acid concentrations depend on the balance 
between addition of amino acids through intestinal absorb-
tion, tissue breakdown, and amino acid synthesis; and 
removal by protein synthesis, other metabolic processes and 
excretion. Intestinal digestion of proteins is the rate 
limiting step in the uptake of free amino acids which are 
quickly absorbed. Increased amounts of dietary proteins 
have little effect on short term fasting levels of 
proteins.3 In a typical experiment to determine the fate of 
ingested protein, dogs were fed a large meat meal. 
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After the amino acids were absorbed in the intestine and 
passed through the portal vein to the liver; it was found 
that 57% were converted to urea, 6% were used in the 
synthesis of plasma proteins, 23% left the liver as free 
amino acids, and 14% remained in the liver presumably to 
form hepatic proteins. Within 15 minutes of absorbtion, 85% 
of free amino acids have been removed from the circulation. 
The liver, pancreas, kidney and intestinal mucosa all have a 
rapid uptake of amino acids. In the brain uptake of amino 
acids is very selective. Uptake of leucine, lysine, and 
proline is slow and there is almost no uptake of glutamic 
acid. Uptake of amino acids by skeletal muscle is slower 
than many other tissues, but muscle maintains a free amino 
acid pool longer than other tissues. Muscle is the largest 
proportion of body mass and therefore can contribute the 
most amino acids to the rest of the body as needed.2 
Protein synthesis and degradation are ongoing pro-
cesses. Each protein has its own half-life with the mean 
survival of all body proteins being about 80 days. Total 
body protein turnover has been estimated to be at least 150 
grams per day, 100 grams of which are supplied by the diet. 
Catabolism of body proteins fills remaining protein 
requirements. 
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Serious alterations of protein metabolism may occur 
after injury depending on severity.4 Simple fractures, 
elective surgery with little loss of blood, and other minor 
injury do not greatly alter body composition.5,6,7 Massive 
injury, severe volume reduction, infection or a combination 
of these are needed to evoke the typical metabolic response 
to injury.5 Body fuels are rapidly mobilized after major 
trauma in excess of their demand.8 Skeletal muscle supplies 
amino acids for hepatic gluconeogenesis, protein synthesis 
and wound repair; however, complete reutilization of amino 
acids does not occur and there is a loss of body nitrogen 
which is greater than losses produced in starvation without 
stress. There is also an increased oxidation of branched 
chain amino acids (BCAA) within skeletal muscles which 
suggest an inability of skeletal muscle to utilize 
non-protein energy substrates.4,9 
Many studies have documented a post-trauma increase of 
whole body protein turnover which can be from 75 to 150 
grams nitrogen per day (300 to 600 glean body mass).7,10,ll 
Whether increased turnover is due to a reduction of whole 
body protein synthesis or an increase in whole body protein 
breakdown has not been determined, and may be dependent on 
the type of injury.ll The effect of trauma on the 
metabolism of individual tissues has also not been fully 
determined. There is some agreement that there is an 
increased synthesis of hepatic non-secretory proteins, but 
results on protein synthesis by muscle are inconclusive.ll 
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Protein loss with trauma can be great enough to impair wound 
repair, resistance to infections, and synthesis of enzymes 
and plasma proteins.9 There has been a great deal of 
interest in trying to correct a patient's negative nitrogen 
balancea to bring about a more speedy recovery. Glucose in-
fusions have been used to spare body protein, but can be 
detrimental to the patient over time if used as the sole 
source of protein sparing therapy without any intake of 
alpha-nitrogen compounds. Glucose spares protein by 
decreasing protein breakdown and causing uptake of free 
plasma amino acids by skeletal muscle presumably through the 
hormonal effects of insulin. The end result of glucose 
therapy can be to cause a decreased supply of essential 
amino acids. Glucose infusions have been shown to limit 
albumin synthesis after trauma,6 while infusions of mixtures 
of essential and non-essential amino acids increase 
albumin synthesis.l2 Amino acid infusions are effective in 
maintaining essential amino acids at concentrations that can 
support protein synthesis.6 
a 
nitrogen 
nitrogen 
excreted 
Nitrogen balance refers to the relative amounts of 
being absorbed and excreted by the body. Thus 
balance is negative if the amount of nitrogen being 
is greater than the amount being taken in. 
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Post-traumatic catabolism of skeletal muscle protein is 
approximately double the amount of whole body catabolism.7 
The branched chain amino acids, valine, leucine, and 
isoleucine are the only amino acids oxidized primarily 
extrahepatically.l3 Under normal conditions, glucose and 
pyruvate inhibit BCAA oxidation.l4 Starvation, stress, 
diabetes and other conditions associated with muscle wasting 
stimulate BCAA oxidation.l4,15 Several regulatory functions 
have been ascribed to BCAA including promotion of protein 
synthesis, inhibition of protein degradation, and stimu-
lation of alanine and glutamine synthesis 13,14 Which, if 
any, of the BCAA individually is regulatory has not been 
determined. Leucine has been implicated in several 
studiesl4,16 while valine has in others.lO These obser-
vations have led to experiments testing the protein sparing 
ability of BCAA infusions. Infusions containing a high 
proportion of BCAA have shown good results in bringing about 
a positive nitrogen balance after trauma in man, and experi-
mental animals.l7,18,19,20 The ability of BCAA infusion to 
improve nitrogen balance increases with their proportion in 
solution until a maximum 32% (weight/weight of alpha 
nitrogen compounds) is reached. Beyond this percentage, 
lack of other amino acids hinders optimal protein syn-
thesis.l5 
Amino acids cannot be stored by the body, and there is 
little accumulation of free amino acids by tissues; there-
fore, rapid utilization of available amino acids must occur 
for optimum protein synthesis.21 All constituent amino 
acids of a protein must also be simultaneously present for 
its synthesis. Amino acid availability for all body cells 
is supplied in the plasma, which maintains their concentra-
tion within narrow limits. These relative plasma 
concentrations of amino acids have been referred to as the 
plasma balance of amino acids.22 Nutritional studies using 
cell free systems (derived from mouse liver)22 multi-celled 
organisms23 (nematodes in axenic culture) and perfused 
heart24 have demonstrated the importance of amino acid 
balance on protein synthesis. 
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The objectives of this study were to evaluate the 
efficacy of a balanced amino acid solution on the recovery 
from temporary liver insufficiency produced by partial 
hepatectomy in rats. A complication of parenteral nutrition 
therapy sometimes seen in patients with liver insufficiency 
is hyperammonemia.25 A second objective of this study was 
to determine the effect of balanced amino acid infusion on 
plasma ammonia concentrations. 
Materials and Methods 
Animals 
Male Sprague-Dawley rats weighing 100 g were obtained 
from Simonsen Laboratories, Gilroy California. Purina rat 
chow and water were provided ad libitum. Rats were weighed 
daily, and allowed to acclimate for a minimum of one week. 
Animals were fasted over night prior to surgery after 
reaching a minimum weight of 150 g. 
Jugular Vein Catheterization 
and Button Implantation 
The method for jugular vein cannulation was a modifi-
cation of Bakar et. al.26 
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Cannula preparation. A 56 em length of medical grade 
silicon rubber tubing (Silastic, Dow Corning Co.) was 
wrapped twice and tied with a 15 em length of 4-0 silk 
suture 28 mm from one end of the tubing. Suture material was 
tied tight enough to avoid easy slippage, yet not so tight 
as to seal the tubing lumen. The knot and wrapped portion 
of suture material was coated with a thin layer of silicone 
rubber aquarium sealant (Dow Corning Co.) and allowed to 
cure at least 24 hours. Cannulas were sterilized by soaking 
in 0.5% benzalkonium chloride for at least l hour before 
implantation (Fig. la, p. 36). 
Cannula needle preparation. The hubs were removed from 
20g x 38mm and 23g x 15 mm needles. The cut ends of both 
needles were then deburred and squared with a very fine 
file. The pointed end of the 23g needle was then honed with 
a whetstone until about 2 to 3 mm would fit snugly and 
securely in the squared end of the l3g needle (Figs. lb and 
lc, p. 36). A bend was gently made in the 20g needle 
approximately 15mm from the pointed end. 
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Polypropylene implant button fabrication (model 1). 
Implant "buttons" were made from polypropylene pipette 
tips for the MLA applicator pipette, 0 to 200 ~1 size. 
Approximately half of the pipette tip from the base end was 
melted over a bunsen burner flame, taking care to avoid 
igniting the polypropylene. The molten end was placed on a 
glass slide and flattened. After cooling and hardening, a 
hole for catheter passage (approximately 2 mm in diameter) 
was made in the center of the base by passing a red-hot wire 
through it. Three other holes (approximately 1 mm in 
diameter) for passage of sutures were placed at equal 
distances around the central hole. The top 7.0 mm, as 
measured from the tip of the pipette, was then cut off. 
Length removed is dependant on catheter and spring catheter 
shield diameters. All rough flashing was trimmed from the 
button surface (Fig. 2, p. 38). 
Polypropylene implant button fabrication (model 2). A 
0-200 ~1 size pipette tip for the MLA applicator was used as 
the main piece for implant button construction. The pipette 
tip is conical in shape, with a base of about 7mm and 
a height of about 48mm. Equidistant around the circum-
ference are three projections about 8mm long running 
lengthwise. Using a red hot needle, a 1 mm hole was placed 
on both sides of these projections, 15 mm from the base of 
the pipette tip. A piece of copper wire about 0.5 mm in 
diameter was threaded through a hole on one side of a 
projection and brought out en the other side. This was done 
for each of the three projections. The ends of each wire 
were twisted together with the ends of adjacent wires, and 
cut to a length of 10 mm. A coat of silicon aquarium 
sealant was applied to the wire tips and allowed to dry for 
at least 24 hours. Fabrication was completed by removing 
13mm of the base and 7 mm of the tip (Fig. 3, p. 40). 
9 
Surgical implantation. Rats were fasted 24 hours prior 
to surgery. Methohexital sodium (40 mg/kg i.p.) was used to 
induce anesthesia followed by pentobarbital (40 mg/kg i.p.) 
4 to 7 minutes later to insure prolonged anesthesia. 
Lidocaine (1%) was given subcutaneously as needed to control 
reflex twitching during implantation. Animals were shaved 
in the neck and midscapular regions after induction of 
anesthesia. (Shaving of animals is not required but makes 
the procedure easier and is recommended.) Whiskers were 
also clipped to reduce the animals tendency to move around 
later in the experiment. 
Animals were restrained in the supine position with 
the head towards the surgeon. In younger rats the jugular 
vein can be seen pulsing under the skin, but may be obscured 
by fat in older animals. A skin incision (1 to 1.5 em long) 
was made over the right jugular vein parallel to the 
animal's midline. In animals where the jugular vein cannot 
be seen, the incision was made 1 to 2 em lateral to the 
midline. The jugular vein was isolated by blunt dissec-
i 
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tion. Care must be taken at this step because excess 
jugular vein manipulation can cause its constriction, making 
cannulation more difficult. (If constriction occurs the 
jugular vein will dilate after a few minutes.) After 
isolating the vein, the cephalic end was grasped with fine 
forceps and a small lancet was used to cut a small opening 
in the vein caudal to the forceps. The implantation needle 
was inserted through the hole and passed along the jugular 
vein. The needle was then passed out of the vein through 
the deltoid muscle, to help control bleeding (Fig. 4a, 
p. 42). Any blood clots formed in the needle during passage 
through the jugular vein were removed by flushing the 
cannula assembly with heparinized saline. The needle was 
carefully disconnected from the cannula and the cannula 
flushed with more heparinized saline to remove any air 
bubbles. The cannula was pulled slowly back until it lay in 
the jugular vein and then advanced towards the heart until 
the knot reached the vein. Cannula blood flow was checked 
by withdrawing the syringe plunger. If no blood could be 
aspirated, the cannula was pulled back until blood flow 
could be obtained. Otherwise the cannula was flushed with 
enough saline to just clear the cannula of blood. Cannulas 
were secured by suturing to the underlying musculature. The 
cannula was clamped with a hemostat and removed from the 
syringe. A wire plug was inserted into the end of the 
cannula and the hemostat removed. 
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The animal was turned over and a 2 to 3 centimeter 
longitudinal skin incision was made in the animal's rnidscap-
ular region. Skin was freed from underlying facia for a 
distance of 1.5 ern in all directions from the incision. A 
hub-less 16 gauge needle was passed subcutaneously from the 
neck incision to the rnidscapular incision (Fig. 4b, p. 42). 
The plugged cannula was threaded through the needle, and 
exteriorized through the mid-scapular incision. The needle 
was removed through the rnidscapular incision leaving the 
cannula in place. A polypropylene button was threaded 
over the cannula and positioned under the skin on the 
animals back, and then sutured to the musculature and skin 
with 4-0 silk. The syringe was reconnected to the cannula 
and blood flow was checked again. If no blood flow was 
obtained, the button was positioned until blood flow 
started. Once sufficient blood flow was obtained the back 
wound was closed with 4-0 silk sutures leaving the button 
tip and cannula protruding (Fig. 4c, p. 42). The neck 
incision was closed using 5-0 silk sutures. The cannula 
was threaded through the protection spring, and the spring 
screwed onto the tip of the button (Fig. 5, p. 44). 
All animals were housed individually and provided rat 
chow ad libitum after jugular vein cannulation. No oral 
water was allowed. 
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Preparation of Solutions 
Balanced amino acid solution. All amino acids except 
glutamic acid were weighed and placed in an Erlenmeyer 
flask. Double distilled water was added and the amino acids 
were dissolved to form a solution of approximately 1.5 times 
the desired final concentration. Glutamic acid was weighed 
and dissolved in double distilled water adjusted to pH = 10 
with saturated NaOH solution. The final concentration of 
the glutamic acid stock solution was ten times the required 
concentration of the final balanced solution. The required 
amount of concentrated glutamate solution was then added to 
the concentrated amino acid solution. To this solution 
Hyperlyte brand of electrolytes were added (25 ml 
Hyperlyte/ lL balanced amino acid solution). Required 
amounts of water-soluble vitamin solutions were added 
(Table 1, p.45). The pH was adjusted to approximately 6.5 
with glacial acetic acid, and then diluted to its proper 
concentration (Tables 2, p. 46, and 3, p. 47). 
Half-normal saline. For each liter of half normal 
saline, 4.25g NaCl was dissolved in double distilled water. 
This solution was then diluted to a final volume of 1.0 
liter. 
Electrolyte solution. For each liter of electrolyte 
solution, 25 ml of Hyperlyte®was added to double distilled 
water, and diluted to the proper volume. 
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Freamine III. One bottle of Hyperlyte®(25 ml) was 
aseptically added to each liter bottle of Freamine®III, and 
was then ready to use. 
Sterilization of solutions. All ingredients were mixed 
thoroughly and placed in a stainless steel container 
attached to a Millipore 90rnrn diameter filter (0.22 micron 
pore size). Solutions were filtered into a sterile Erlen-
meyer flask using ultra-pure nitrogen as the propellant. 
Solutions were poured into sterile infusion flasks under a 
laminar air flow hood, and plugged with a sterile rubber 
stopper after filtration. 
Partial Hepatectomy 
One-half normal saline was infused continuously (30 
ml/d) via the jugular vein for 72 hours following cannu-
lation. Animals were provided with rat chow ad libitum 
during the first 48 hour of this period, and were fasted 
during the next 24 hours prior to partial hepatectomy. 
Each rat was anesthetized with methohexital sodium 
injected through the jugular cannula. The dose of metho-
hexital was titrated individually for each animal by 
observing response to painful stimuli and breathing rate. 
Once an adequate plane of anesthesia had been reached, 
animal's were placed on their backs in a V shaped operating 
board constructed from half inch wire mesh. This was 
necessary because of the protruding implant button and 
spring apparatus on each animal's back. The springs were 
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folded back under the animals with the swivels and tails 
facing the investigator. Additional anesthetic could easily 
be given as needed during surgery with the animals in this 
position. 
A midline ventral abdominal skin incision was made from 
just above the xiphoid process to about half way down the 
abdomen (Fig. 6a, p. 49). An incision was then made through 
the abdominal muscles from about mid way on the abdomen to 
the xiphoid process. The falciform ligament which extends 
along the midline from the convex face of the liver to the 
diaphragm was cut. A bolster was then placed under the 
animal to arch his back, and a piece of gauze was placed at 
the caudal end of the incision. Using finger tips the left 
lateral lobe of the liver was gently pulled part way out of 
the abdominal cavity, and the suspensory ligament which 
connects the left lateral lobe to the hepatic portal vein 
was cut. The median lobe was "popped'' out of the abdominal 
cavity by squeezing and pushing down on the abdorrten just 
below the rib cage with the left hand and maintaining gentle 
traction on the left lateral lobe with the fingers of the 
right hand (Figs. 6b and 6c). Traction was maintained on 
both exteriorized lobes with the left hand while the right 
hand put a ligature around them and their blood vessels. 
The ligature was tied (Fig. 6d), and the lobes were placed 
on gauze pads, Several cuts were made in each lobe so blood 
would be absorbed by the gauze, and not drip into the 
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abdominal cavity when the lobes were severed (Fig. 6e). The 
lobes were then transected and removed. Any excess ligature 
material was also removed. Muscular incisions were closed 
with a continuous suture using 4-0 silk. Skin incisions 
were closed with 9mm stainless steel wound clips. After 
surgery animals were returned to their cage and an infusion 
of half-normal saline was started until animals reqained 
consciousness, whereupon a test solution was started. 
Experimental Groups 
Animals were divided into 5 groups following partial 
hepatectomy . Group IA was provided with rat chow ad 
libitum, and infused with half-normal saline. Group IB was 
® provided with rat chow ad libitum and infused with Hyperlyte 
(Kendall-Me Gaw Inc.) electrolyte solution. Group II was 
provided with oral glucose pellets ad libitum and infused 
with Freamine®III. Group III was provided with oral 
glucose pellets ad libitum, and infused with the balanced 
amino acid solution. Group IV han a sham oartial henatec-
tomy. Food and infusion for this groun was the same as for 
GrouP IB. The infusion rate for all solutions was 30 
ml/day (Table 4, p. 50). 
Sample Collection 
A 1 ml syrinqe with a blunt 22g needle was filled 
with 0.2 ml of sodium heparin. In order to prevent air from 
entering the cannula, the distal end of the cannula was 
clamped with a fine hemostat prior to detaching the cannula 
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from the swivel. The cannula was detached from the swivel 
and the blunt syringe needle was inserted into the cannula, 
and the clamp released. A 0.8 ml of blood was then aspir-
ated into the syringe. The syringe was held vertically 
with the needle pointing downward to prevent dilution of 
blood by the heparin solution during blood aspiration. The 
cannula was again clamped and the needle removed after 
aspiration. The ·blood sample was injected into three sodium 
heparin treated glass capillary tubes and one plain glass 
capillary tube (0.2 ml total). Capillary tubes were sealed 
with Seal Eze and centrifuged for 5 minutes in a hematocrit 
centrifuge. Immediately after centrifugation, plasma was 
separated from red cells and placed into Dispo beakers, 
covered with Parafilm and placed on ice. Any remaining 
blood and heparin in the syringe was re-injected through the 
cannula into the animal. 
Samples were collected at the following times: 
l. 
2 . 
3. 
4. 
5. 
6 . 
48 
24 
48 
96 
144 
19 2 
hours after cannulation ( 2 4 hours prior 
partial hepatectomy) 
hours after partial hepatectomy 
hours after partial hepatectomy 
hours after partial hepatectomy 
hours after partial hepatectomy 
hours after partial hepatectomy. 
to 
-
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Assays 
Initial assays on group IA were done in triplicate. 
All other group assays were done singly. All spectrophoto-
metric measurements were done on a Carl Zeiss spectrophoto-
meter model PMQ II. 
Lactate Dehydrgenase (LDH) Assay 
Materials. All chemicals for the LDH assay were 
obtained from Sigma Chemical company, St. Louis, MO. 
Pyruvate substrate, Stock No. SOOL-1, Lot No. 123F-6110, 
0.75 mmol/1 sodium pyruvate in a buffered solution. 
Color reagent, Stock No. 505-2, Lot No. 102F-6060, 
2,4-dinitrophenylhydrazine, 20 mg/100 ml, in 1.0 N HCl 
NADH, Stock No. 340-101, Lot No. 612-F4, 
NADH 1.0 mg (dissolved in pyruvate solution prior to 
assay). 
0.4 N NaOH 
Method. In a small beaker, 10 ~1 of serum was mixed 
with 50 ,~1 of double distilled water. The substrate 
solution was made by adding 1.0 ml of the pyruvate solution 
to a vial of NADH and gently mixing. One hundred ~1 of this 
solution was then placed in a 10 x 50 mm test tube and put 
into a 370 water bath for a few minutes to equilibrate 
temperatures. After equilibration, 10 ~1 of diluted serum 
was added to the substrate in the test tube and placed in 
the water bath for 30 minutes. The tube was removed from 
the water bath and 100 ~1 of color reagent was added, and 
mixed. After 20 minutes, 1.0 ml of 0.4 N NaOH was added, 
and mixed. Absorbance was read at 505 nm after five 
minutes. LDH activity was then calculated from a standard 
curve (Fig. 7, p. 52). 
LDH standard curve. (See table 5, p. 53 for contents 
of each tube for the standard curve). Approximately 20 
minutes after the addition of the color reagent to the 
tubes, 1.0 ml of 0.4 N NaOH was added to each tube. 
Absorbance was read at 505 nm five minutes later. 
Ammonia Assay 
Materials. All reagents were obtained from Sigma. 
Sigma Ammonia Reagent No. 170-3 Lot No. 35F-6110 
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Sigma L-Glutamate Dehydrogenase Solution, No. 170-4 Lot 
No.637-F5 
Sigma Ammonia Control Solution, No. 170-5, Lot No. 
l5F-6137 
Method. The ammonia assay is a modified version of 
Sigma's ammonia assay. Each ammonia assay was carried out 
in a micro-volume quartz cuvette. In a cuvette, 300 ~1 of 
ammonia reagent was gently mixed with 20 ~1 of plasma. 
Initial absorbance wa~ read at 340 nm. After standing at 
room temperature for five minutes. Glutamate dehydrogenase 
(2.0 ~l) was added to the cuvette, gently mixed, and allowed 
to sit at room temperature for five minutes. Final ahsorb-
ancP waR read a~ 340 nm. A blank anA control were AonP for 
ea~h groun of assays. Water and ~on~rol solutionR were 
substituted for plasma in the preparation of the blank and 
control respectively. 
Ammonia concentration was found by subtracting the 
final absorbance from the initial absorbance, and multi-
plying by a factor of 13.6. Ammonia concentration of the 
blank was subtracted from the plasma value. 
Bilirubin Assay 
Materials. All chemicals were obtained from Sigma. 
Caffeine reagent. Stock No. 605-2, Lot No. 24F-6090, 
Caffeine, 25g/L, and Sodium benzoate 38g/L in sodium 
acetate solution. 
Alkaline tartrate, Stock No. 605-3, Lot No. 24F-6089, 
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Sodium potassium tartrate, 350 g/L, in sodium hydroxide 
solution. 
Hydrochloric acid, Stock No. 945-50, Lot No. 63F-6115, 
0.05 N HCl. 
Diazo reagent, Stock No. 605-7, Lot No. 24F-6087, 
75 ~mol sulfanilic acid, and 6.6 mol sodium nitrite. 
(Reconstituted with 6 ml HCl 0.05 N prior to use.) 
Cysteine reagent, Stock No. 605-6, Lot No. 24F-6088, 
Cysteine hydrochloride, 100 mg in 10.5 ml water. 
Method. (See table 6, p. 54 for contents of each 
tube). 
Absorbance was read at 600 nm. within 30 minutes of addition 
of alkaline tartrate. Bilirubin concentration was calcu-
lated by multiplying absorbance by 44. 
Glutamic Pyruvic Transaminase (GPT) Assay 
Materials. All reagents were from Sigma. 
Alpha-ketoglutarate substrate, Stock No. 505-51, Lot No. 
43F-6111. 
Color reagent same as used in LDH assay). 
0.4 N NaOH 
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Method. One hundred ~1 of alpha-ketoglutarate 
substrate was added to a 9 x 70 mm test tube, and placed in 
a 37° water bath for a few minutes to equilibrate temper-
ature. After equilibration, 20 ~1 of plasma was added, and 
the tube was replaced in the 37° water bath. Exactly 30 
minutes later, 100 ~1 of color reagent were added, mixed, 
and allowed to stand at room temperature for 20 minutes 
before adding 1.0 ml of 0.4 N NaOH. Color was allowed to 
develop for five minutes before being read at 505 nm. GTP 
activity was determined from the standard curve (Fig. 8, 
p. 56). 
GPT standard curve. (See table 7, p. 57 for the 
contents of each tube used in constructing the standard 
curve). 
Results 
Animal Viability 
The over all survival of animals varied considerably 
between groups, and somewhat within groups. Two animals in 
the Freamine group died on the last day of the experiment. 
All other animals in this group finished the experiment. 
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Animals infused with the electrolyte solution had the 
shortest mean survival time ( mean= 8.67 days, s.d. = 2.05) 
The sham surgery and balanced formula groups had inter-
mediate mean survival times (Table 8a, p.58). 
A complete autopsy was not done on the animals and thus 
an exact cause of death cannot be determined. Post mortem 
examination yielded consistent findings which could have 
caused death of animals. A yellow colored "plaque" was found 
in the vena cava and atrium in 8 of the 10 animals which 
died prior to the finish of the experiment. Animals that 
finished the experiment did not have "plaque" occluding the 
heart. Only 1 animal which died showed signs of liver 
failure. This animal died 72 hours after partial hepatec-
tomy and was being infused with the balanced formula. One 
remaining animal which did not finish the experiment 
accidentally asphyxiated itself while trying to escape from 
its cage. 
Weights were measured just prior to cannulation and at 
the end of the experiment or time of death. Animals infused 
with the electrolyte solution had the greatest weiqht loss 
of all groups (mean= 88.99% of baseline). The sham 
surgery group had a mean = 95.71% of baseline. Average 
weights of the balanced group and the Freamine group was 
essentially equal at the start and finish of the experiment 
(Table 8b). 
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LDH Assay 
Early experiments with saline infused controls did not 
show any change in serum LDH activity at any sampling time. 
As a result of this finding, this assay was not done on any 
other experimental group (Fig. 9, p. 60). 
Hematocrit 
There was a decrease in hematocrit after partial 
hepatectomy, with the lowest hematocrit values at 96 hours 
after the surgery in the Freamine and sham groups. The 
lowest hematocrit values for the balanced and electrolyte 
groups were at 144 hours and 48 hours respectively. 
Hematocrit did not continue to fall with repeated blood 
sampling. Hematocrit values for all groups were somewhat 
higher at the end of the experiment than values recorded 
during the previous two samplings. The sham surgery group 
had a final hematocrit equal to 103% of the initial, which 
was the highest value of all groups (Fig. 10, p. 62). 
Direct Bilirubin 
In this study direct bilirubin is bilirubin which is 
not bound to any plasma proteins. Direct plasma bilirubin 
levels for the Freamine and the balanced groups approxi-
mately doubled in the first 24 hours after partial hepatec-
tomy then returned to normal in the following 72 hours. 
Bilirubin levels for the saline and sham control groups 
stayed approximately at baseline levels throughout the 
experiment. The initial bilirubin level for the sham 
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group (0.25 mg/dl) was lower than the saline (2.46 mg/dl) 
and balanced (1.35 mg/dl) groups (p < 0.025). The bilirubin 
level 24 hours after partial hepatectomy for the Framine 
group (3.64 mg/dl) was greater (p < 0.01) than the sham 
group (0.34 mg/dl). The balanced group bilirubin value 
(3.63 mg/dl) was greater (p < 0.05) than the saline group 
(2.17 mg/dl). The balanced group (1.14 mg/dl) was lower 
(p < 0.025) than the Freamine group (2.28 mg/dl) and lower 
(p < 0.05) than the saline group (2.22 mg/dl) 96 hours after 
partial hepatectomy. The Freamine group bilirubin value 
(1.58 mg/dl) was lower (p < 0.025) than the saline group 
(2.27 mg/dl) 144 hours after the partial hepatectomy. Any 
difference between the groups 48 hours and 192 hours after 
the partial hepatectomy could not be determined with any 
reliability due to the large standard deviation and/or small 
number of samples (Table 9, p. 65, and Fig. 11, p. 64). 
Total Bilirubin 
Total bilirubin in this study was the measurement of 
free plasma bilirubin and plasma protein bound bilirubin. 
Total bilirubin levels for the Freamine and sham groups 
peaked 24 hours after partial hepatectomy. The balanced 
group and electrolyte group peaked 48 hours after surgery. 
Values for the saline group remained relatively constant 
during the experiment. The initial bilirubin value of the 
saline group (2.29 mg/dl) was greater (p < 0.05) than any 
other group. The initial bilirubin value for the balanced 
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group (1.28 mg/dl) was greater (p < 0.025) than that of the 
sham group (0.33 mg/dl). Comparison between groups 24 hours 
after partial hepatectomy could not be made with any 
reliability due to the large standard deviations of the 
groups. 48 hours after partial hepatectomy, bilirubin 
value of the balanced group (6.25 mg/dl) was greater 
(p < 0.25) than the Freamine group (3.66 mg/dl). Both of 
these groups were also greater (p < 0.05) than the saline 
value and greater (p < 0.1 for the balanced group and 
p < 0.025 for the Freamine group) than the sham group. The 
Freamine group bilirubin level was still elevated above the 
saline group at 96 hours (p < 0.025) and 144 hours 
(p < 0.005). The balanced group bilirubin level 
(0.49 mg/dl) was also lower (p < 0.005) than the saline 
(2.40 mg/dl) and Freamine (2.58 mg/dl) groups at 144 hours. 
There was no significant difference between groups at 192 
hours after partial hepatectomy (Table 10, p. 68, and 
Fig. 12, p. 67). 
Plasma Ammonia Levels 
Data from all groups were averaged together to find a 
baseline plasma ammonia concentration ( mean= 2.97~g/ml, 
s.d. = 8.10). Plasma ammonia increased in the Freamine 
group 24 hours after partial hepatectomy (3.64 ~g/ml), but 
decreased in the balanced (2.23 .~g/ml) and sham (1.07~g/ml) 
groups. Ammonia levels fell below baseline values for all 
groups during the next 24 hours. Sham group data is not 
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reliable after the 48 hour sampling time because of diffi-
culties in obtaining samples from a large enough population 
of animals. Determination of ammonia levels at the 96 hour 
sampling time was not possible because of technical diffi-
culties with ammonia standards. Ammonia levels for the 
Freamine (1.77 ~g/ml) and the balanced (0.96 ~g/ml) groups 
were below baseline levels 144 hours after partial hepatec-
tomy (Fig. 13, p. 70). 
GPT Assay 
The GPT activity increased for all groups after partial 
hepatectomy. The low baseline reading for the sham group 
was due to a bad NaOH reagent. Sham group GPT values were 
fairly constant and the lowest (p < 0.005) of any group 
during the experiment. GPT values for the electrolyte 
controls were the highest (p < 0.005) at all sampling times 
measured. Freamine and balanced groups were back to 
baseline levels by 96 hours after surgery. The Freamine 
group had the least increase in GPT activity of all part-
ially hepatectomized groups. Saline group GPT activity 
(181.18 S.F.units) was greater (p < 0.05) than the balanced 
group (116.54 S.F.units) and (p < 0.01) the sham group (79.9 
S.F.units) 24 hours after partial hepatectomy. Saline group 
GPT activity was still elevated above other groups 48 hours 
after partial hepatectomy. The Freamine group (11.35 S.F. 
units) had a lower (p < 0.025) GPT activity than the 
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balanced group (28.21 S.F. units) 96 hours after partial 
hepatectomy. No other statistically significant differences 
could be found in the remaining data (Table 11, p. 71, 
and Fig. 14, p. 73). 
Discussion 
The literature provides several methods for jugular 
vein cannulation. Many of these are essentially the 
same.27,28,29 While these procedures were adequate, they 
sometimes took an inordinately long time. This was usually a 
result of failing to get the catheter in the vein on the 
first attempt, and having the vein constrict making subse-
quent attempts difficult. The method of Bakar and Niazi 
proved to be more efficient than other cannulation tech-
niques tried in this study. The initial. extra preparation 
time of this method was negated by the ease and speed with 
which this procedure could be carried out. With this method 
it was possible to have a 100% success rate. 
If animals are to be cannulated for continuous infusion 
of any solution, then the cannula must be protected from the 
rat and its tendency to chew anything available. Stress 
induced by restraining cages precludes their use in long 
term studies such as this one. Two methods which allow 
animals freedom of movement and cannula protection are the 
use of a swivel-spring assembly connected to a harness/jac-
ket or to an implant button. While all of these methods 
cause some stress to the animal, the implant button is the 
least stressful.30 Both of these methods were tried in 
this study. Jackets were hard to adjust to a proper fit. 
Even if they were adjusted properly there was an unaccept-
able escape rate. Jackets also had a tendency to cause 
head, neck, and forearm edema. Use of implant buttons 
caused no edema, and the escape rate was zero. 
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Jugular vein cannulation for continuous nutrient 
infusion in rats has been successfully done by a number of 
researchers. Rats totally fed by this method have been 
maintained for as long as 40 days.28 Maintenance of cannula 
patency for blood sample collection is a different story. 
In this experiment, the longest time that any samples could 
be collected from any animal was 16 days after cannula-
tion. This was achieved in only 10% of the population (Fig. 
15, p. 75). A study comparing various cannulation sites and 
maintenance of patency had a 50% success rate on day 14.31 
Animals in both the Freamine and balanced groups main-
tained weight, even after losing about 10 grams following 
partial hepatectomy. The sham and electrolyte control 
groups lost 4.25% and 11.01% respectively. These findinqs 
are not in agreement with reported values which were on the 
order of a 15% weight loss for all experimental 
qroups.l0,13,15 the reason for this discrepancy is not 
known. 
A somewhat distressinq finding of this study was a 
high animal attrition rate. A factor common in many animals 
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which died, or were terminated because no blood samples 
could be obtained was the appearance of a yellow colored 
"plaque" in the right atrium and vena cava. It is assumed 
that this plaque is a thrombus formed of platelets. 
Thrombus formation is a well known complication of paren-
teral nutrition therapy occurring with a frequency of 6.5 to 
21% 32 In this study a thrombus formed in the vena cava 
and atrium in 50% of all experimental animals. Of all 
animals which died before the end of the experiment, 64% had 
a thrombus. Three other animals (15%) were terminated prior 
to the end of the experiment due to cannula blockage by 
thrombi. The Freamine group had the lowest frequency of 
thrombus formation. All of the other groups had approx-
imately the same frequency. The reason for these differ-
ences are not known. Factors known to be associated with 
thrombus formation include: endothelial damage during 
catheter insertion, a break in sterility or the presence of 
a foreign body. These factors really do not account for any 
difference between the Freamine and other groups since the 
same experimental methods were used in all groups. Thus it 
would be expected that thrombus formation should have 
occurred with an equal frequency in all groups. An unknown 
thrombogenic factor may have inadvertently been incorporated 
into infusion solutions as residue on glassware or remained 
in solution after distillation and filtration. 
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Extreme hypertonicity of the infusion solutions could 
be another possible reason for the overall higher rate of 
thrombus formation. Infusion of a hypertonic solution into 
a large bore vessel is usually not a problem due to rapid 
mixing and dilution of the infusate. Thus hypertonic 
solutions may be safely infused into the vena cava whereas 
the same solution infused into a peripheral vein would cause 
problems. In total parenteral nutrition of man, the ratio 
of area between the outside cannula diameter and the inside 
vein diameter is 0.20 to 0.25. In this study the ratio was 
0.56. Thus it is possible that the solutions were too 
hypertonic for infusion into small diameter veins and atria 
of rats. 
The relation between elevated plasma bilirubin levels 
producing jaundice and hepatic di~ease or injury has been 
established for some time. Normal plasma concentrations of 
bilirubin are 0.1 to 0.4 mg/dl for direct bilirubin and 0.1 
to 1.3 mg/dl for total bilirubin in humans.33 Plasma 
bilirubin concentrations for rats are also approximately 0.3 
mg/dl depending on species.34 Jaundice becomes clinically 
apparent at plasma concentrations above 2.0 mq/dl.35 
Carbon tetrachloride and other hepatotoxins have been 
reported to produce an increase in plasma bilirubin lasting 
6 weeks after administration.36 Regenerating liver shows 
a decreased ability to excrete bilirubin into the bile 
during the first 24 hours after partial hepatectomy.37 The 
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maximal rate of bilirubin excretion has been shown to be 
depressed by 80% after 70% hepatectomy, which is a 20 to 30% 
greater decrease than expected.38 Hepatic uptake of bili-
rubin has also been shown to decrease after partial hepatec-
tomy returning to normal ranges 4 days later. The mech-
anism behind this decrease is not known but is thought 
to be a result of a decreased amount of organic anion 
binding protein in the immature hepatocyte plasma mem-
brane.39 Despite these findings several studies have 
been unable to document any increase in plasma levels of 
endogenous bilirubin after 70% partial hepatectomy.40,41 
An increase was reported after 80% sub-total hepatectomy.40 
In this study there was no increase of plasma bilirubin in 
sham, saline or electrolyte groups. A large increase was 
seen in the balanced group. Two animals in this group had a 
continual increase of their plasma bilirubin after partial 
hepatectomy. Neither animal finished the experiment and 
both had extensive yellow discoloration of their livers 
during post mortem examination. A slight increase was also 
seen in the Freamine group during the first 48 hours after 
partial hepatectomy. Bilirubin levels calculated for the 
saline, balanced and Freamine groups all were higher than 
the accepted normal range. Reasons for these high readings 
are not known and therefore cast some doubt on the reli-
ability of the quantitative bilirubin results. However, 
plasma did become yellow colored after partial hepatectomy 
in these groups indicating a qualitative presence of 
bilirubin. 
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Glutamic pyruvic transaminase (GPT) is found in high 
concentrations in liver and low concentrations in other 
tissues. GPT is released into the blood by the lysis of 
necrotic hepatocytes. In man plasma GPT concentrations 
range from 0 to 21 SF units/ml.42 Rat plasma usually has 
GPT activity in the upper end of the human range.34 
Several studies have documented elevated plasma GPT levels 
following partial hepatectomy. Maximal levels occurred 12 
hours after partial hepatectomy and gradually returned to 
normal ranges on the fourth post operative day. The degree 
of plasma GPT elevation was correlated with the amount of 
liver removed.38,40 Results of this study are in general 
agreement with the above findings. A discrepancy with the 
above findings was the increased plasma GPT activity of the 
sham group after partial hepatectomy. GPT activity for this 
group remained above baseline values at all sampling times. 
Sham group data must be viewed with some cautionis since it 
is based on a small number of animals, especially after the 
48 hour point. Both the Freamine and balanced groups had 
lower increases in plasma GPT activity than the saline 
group. This suggests that hyperalimentation infusions 
provided cells injured during surgery with better nutri-
tion and thus prevented their death and subsequent release 
of GPT. 
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Normal plasma ammonia concentration in humans ranges 
from 80 to 110 g/dl.35 A literature search failed to find 
the normal range of plasma ammonia in the rat. In this 
study, a baseline value of 297 g/dl was found. Rats 
infused with the balanced formula had plasma ammonia levels 
below baseline at all sampling times after partial hepatec-
tomy, and they were also lower than levels in rats infused 
with Freamine III. This suggests that a balanced amino 
acid solution can be infused without causing hyperammonemia 
in rats with temporary hepatic insufficiency. However, the 
above needs to be viewed with some caution. A large 
standard deviation and/or a small population within each 
group made any statistical difference between groups 
questionable. Ammonia standards were also subject to 
occasional irregularities casting some doubt on the overall 
precision of some individual ammonia determinations. 
Although ammonia results seem rather high, they are 
still lower than elevated plasma ammonia values recorded in 
serious hepatic disease which may exceed 1000 g/dl.43 If 
the plasma ammonia levels are truly as high as the data 
suggest, one of several possibilities may explain why. 
Patients should be fasted at least 6 hours before samples 
are taken for plasma ammonia determination.44 Dietary 
protein and the infusion of crystalline amino acids in 
solution are both known to increase plasma ammonia concen-
tration.45 Another possibility is environmental ammonia 
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intoxication. The recommended maximum allowed air ammonia 
concentration in the work place for man is 25 ppm (8 
hr/day, 5 day/week). Rat cages frequently have concen-
trations above this level.46 
In an attempt to conserve animals, this experiment was 
designed so blood samples would be collected from each 
animal at each sampling time. In order to do this while 
minimizing the effects of repeated blood sampling, each 
sample was just large enough to permit one trial of each 
assay. Thus it was not possible to double check any values 
which seemed unusual. Each assay was also scaled down by a 
factor of ten to conserve blood in the animals. Such small 
samples may have decreased assay precision. 
The objectives of this study were to evaluate the 
efficacy of a balanced amino acid infusion on recovery from 
temporary hepatic insufficiency, and their effect on plasma 
ammonia levels. While results of the LDH and bilirubin 
assays were inconclusive, the GPT assay suggests that the 
balanced formula was as effective as Freamine III in 
minimizing inflammation and necrosis of remaining hepato-
cytes after partial hepatectomy. Data from the ammonia 
assay suggests that the balanced formula was more effective 
than Freamine III in maintaining plasma ammonia levels 
within the normal range after partial hepatectomy. Diffi-
culties with animal viability and cannula patency seen 
in the balanced formula group were no worse than seen with 
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the electrolyte controls, suggesting that these problems 
were not a directly related to the balanced formula's amino 
acid composition. Unfortunately, the results of this study 
were not totally conclusive. More work needs to be done to 
fully evaluate the therapeutic potential of amino acid 
balanced solutions. Perhaps with a different experimental 
model, assays with greater sensitivity, and a cooperative 
team effort, it may be possible to fully validate this 
concept. 
Figure la. Catheter used for infusing solutions into the 
jugular vein (modified from Bakar et.al.26). 
Figure lb-ld. Preparation of implant needle 
detail, from Bakar et.al.26). 
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Figure 2. Fabrication of Implant Button ~Model 1), 
Using a MLA 0 - 200 Microliter Polyethylene 
Pipette Tip. 
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Figure 3. Fabrication of Implant Button (Model 2), 
Using a MLA 0 - 200 Microliter Polyethylene 
Pipette Tip. 
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Figure 4a. Insertion of implant needle and catheter into 
jugular vein. Note that the needle is brought 
out through the deltoid muscle. (modified from 
Bakar26). 
Figure 4b. Securing the catheter and tunneling under the 
skin (modified from Bakar26). 
Figure 4c. Exteriorization of catheter and implant button. 
(from Bakar26). 
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(b) 
Figure 5. Cannulated animal and swivel assembly. 
Animal is shown with implant button. 
(Modified from King-Chatham47). 
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TABLE 1 
Vitamins and Electrolytes Added 
to Amino Acid Solutions 
Viatmins g/1 
Choline 40.62 
Folate 0.03 
Niacin 0~6 
Pantothenic acid 0.24 
Riboflavin 0.09 
Thiamin 0.14 
B6 0.22 
Bl2 0.002 
Electrolytes meq 
Sodium 25 
Potassium 20 
Calcium 5 
Magnesium 5 
Chloride 30 
Acetate 25 
total mOsm/L 4200 
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TABLE 2 
Amino Acid Concentration of Serum 
and 10% Balanced Formula 
AMINO M.W. serum(l) serum serumlO% Balanced 
ACID (nmol/ml) (mg/1) (mg/1) (mg/1) 
ILE 131.20 54.94 7.21 1633 1635 
LEU 131.20 98.70 12.95 2934 2927 
LYS 146.20 127.30 18.61 5274 5276 
MET 149.20 48.05 7.17 1624 1622 
PHE 165.20 40.80 6.74 1527 1530 
THR 119.20 219.30 26.14 5923 5930 
TRP 204.20 127.35 26.00 5892 5890 
VAL 117.20 135.20 15.85 3590 3592 
~ 
ALA 89.10 379.50 33.81 7661 7672 
ARG 174.20 185.55 32.32 7324 7326 
HIS 155.20 47.25 7.33 1662 1676 
PRO '115.20 740.45 85.30 19327 19349 
SER 105.20 200.30 21.07 4774 4792 
TYR 181.20 66.05 11.97 2712 200 
GLY 75.10 270.05 20.28 4595 4602 
CYS-HCl 121.20 34.75 4.21 955 956 
GLU 147.10 130.45 19.19 4348 4330 
ASP 133.10 30.10 4. 01. 908 910 
GLN 146.10 505.15 73.80 16722 16727 
ASN 132.10 55.85 7.38 1901 1920 
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TABLE 3 
Comparison of Freamine III and balanced formula 
amino acid composition 
AMINO Balanced Freaminei Molar ratio (Leu based) 
ACID (mg/1) (mg/1) serum Balanced Freamineiii 
ILE 1635 6900 0.56 0.56 0.76 
LEU 2927 9100 1. 00 1. 00 1. 00 
LYS 5276 7300 1. 29 1. 62 0.72 
MET 1622 5300 0.49 0.49 0.51 
PHE 1530 5600 0.41 0.42 0.49 
THR 5930 4000 2.22 2.23 0.48 
TRP 5890 1500 1. 29 1. 29 0.11 
VAL 3592 6600 1. 37 1. 37 0.81 
ALA 7672 7100 3.84 3.86 1.15 
ARG 7326 9500 1. 88 1. 88 0.79 
HIS 1676 2800 0.48 0.48 0.26 
PRO 19349 11200 7.50 7.53 1. 40 
SER 4792 5900 2.03 2.04 0.81 
TYR 200 0.67 0.01 0.00 
GLY 4602 14000 2.74 2.75 2.69 
CYS-HCl 956 240 0.35 0.35 0.03 
GLU 4330 1. 32 l. 32 0.00 
ASP 910 0.30 0.31 0.00 
GLN 16727 5.12 5.13 0.00 
ASN 1920 0.57 0.65 0.00 
Figure 6. Partial Hepatectomy Proceedure 
a. ·abdominal insicion 
b. "poping" the liver (medial and left lateral lobes) 
out of the abdominal cavity. 
c. suspensory ligaments cut during the procedure. 
d. ligature placement. 
e. preperation for liver transsection 
(all from Waynforth27). 
b. 
Gauze 
bolster 
··· lobe ft lateral 
Le face l (dorsal 
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lobe Median face l (dorsal 
Gauze pad 
Median lobe 
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Median 
lobe 
d. 
Blood 
vessels 
49 
Left 
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TABLE 4 
Group designation and variables. 
Group Surgery Infusion { 1 ) . Food { 2) • 
IA. Part. Hep. Half Normal Rat Chow 
{Saline) Saline 
IB. Part. Hep. Hyperlyte Rat Chow 
{Electrolyte) Electrolytes 
II. Part. Hep. Freamine III Glucose 
{Freamine) Amino acids Pellets 
III. Part. Hep. Balanced Form. Glucose 
{Balanced) Amino acids Pellets 
IV. Sham Hyperlyte Rat Chow 
{Sham) Electrolytes 
{1). Infusion rate for all solutions was 30 mL/day. 
{2). All food was provided ad libitum. 
Figure 7. Standard Curve for Lactate Dehydrogenase Assay 
Each point is based on nine determinations. 
1..: 
(1) 
> J... 
::l (.) 
, 
J... 
ca 
-c 
t: 
ca 
...... 
en 
J: 
c 
..J 
c.o 
0 
• 
• 
N 
c:i 
aoueqJosq\f 
• 
• 
0 
0 
0 
N 
0 
M 
10 
"!'"" 
0 
lll::t 
·0 
"!'"" 
0 
ll::t 
c.o 
0 
co 
N 
0 
52 
>-... 
·-> 
·-... (.) 
<( 
J: 
c 
..J 
tube # 
1 
2 
3 
4 
5 
6 
Notes: 
53 
Table 5 
LDH Standard Curve Tube Contents 
Pyruvate water color reagent LDH act. 
100 10 100 0 
80 ::0 100 280 
60 50 100 640 
40 70 100 1040 
20 90 100 1530 
10 100 100 2000 
1. Values listed for pyruvate, water and .color reagent 
are microliters 
2. 20 min. after mixing the above reagents, 
1.0 ml of 0.40 N NaOH was added to each tube 
3. LDH activity is in Berger-Broida units per ml 
{1 IU LDH activity= 0.48 B-B unit/ml) 
54 
TABLE 6 
Bilirubin assay tube contents 
component plasma total direct 
blank 
serum 20 20 20 
HCl 50 0 100 
Caffeine 100 100 0 
Diazo reagent 0 50 50 
Cysteine 10 10 10 
Alkaline Tartrate 150 150 150 
Notes: 1. Above values are microliters 
2. Concentrations of reagents are listed 
under methods. 
Pigure 8. GPT Standard Curve 
Each Point is based 
on nine determinations 
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TABLE 7 
GPT Standard Curve Tube Contents 
Calibration substrate water GPT 
standard activity 
0 100 20 0 
10 90 20 23 
20 80 20 50 
30 70 20 83 
40 60 20 125 
1. 100 microliters of Sigma color reagent was 
added to each tube after the above reagents 
were mixed together. 
2. 20 min after adding the color reagent, 
1.0 ml of 0.4 N NaOH was added to each tube. 
3. Reagent volumes listed are microliters 
4. Activity is in Sigma-Frankel units/ml 
(1 IU GPT activity= 0.48 S-F unit/ml). 
group 
Freamine III 
Balanced 
Electrolyte 
Sham 
Freamine III 
Balanced 
Electrolyte 
Sham 
key 
Probable 
a 
60% 
40% 
20% 
TABLE 8 
Animal viability 
avg 
14.00 
11.00 
8.67 
12.67 
Cause 
Suvival Time 
S.d. 
0.00 
2.76 
2.05 
1. 89 
of Death 
b 
20% 
40% 
60% 
20% 
a. finished the experiment 
b. thrombus 
c. hepatic failure 
var 
0.00 
7.62 
4.20 
3.57 
c d 
20% 
60% 
d. terminated due to sampling problems 
e. accidental death 
Weight Change 
Cannulation Final Percent 
Group Weight Weight Change Change 
Freamine 140.60 142.00 1. 40 101.00 
Balanced 138.20 139.50 1. 25 100.94 
Electrolyte 159.00 141.50 -17.00 88.99 
Sham 155.33 148.67 -6.67 95.71 
e 
20% 
40% 
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Figure 9. LDH activity after partial hepatectomy 
in saline control animals. Results are 
averages of five animals. A triplicate 
determination was made for each animal. 
Dashed line represents 0 activity, and 
activity increases as absorbance decreases. 
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Figure 10. Hematocrit values after partial hepatectomy. 
0.2 ml of blood was removed at each sampling 
time. Results are expressed as a percentage of 
presurgery values and are averages of all 
animals within each group. 
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Figure 11. Direct plasma bilirubin levels after partial 
hepatectomy. Group values are averages of single 
determinations from each animal. 
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TABLE 9 
Direct Plasma Bilirubin 
Group 0 hr 24 hr 48 hr 96 hr 144 hr 144 hr 192 hr 
Freamine III avg. 3.64 1. 9 3 * 2.28• 1. 58 1. 58 2.24 
s.d. 1.04 0.5 0.32 0.09 0.09 0.61 
n 4 4 3 2 2 2 
Balanced Avg. l. 35 4.49 3.63 1.14 
S.d. 0.47 1. 73 0.22 
n 4 l 5 3 
Saline avg. 2.46 1. 87 2.17 'f. 'f.. 2.22 ** 2.27 2.27 1. 92 
s. d. 0.17 0.47 1. 02 0 0.09 0.09 0.5 
n 4 4 4 2 2 2 2 
Sham avg. 0.25 0.34 
s.d. 0.01 0.07 
n 3 2 
* p < 0.1 ** p < 0.05 *** p < 0.025 
0'1 
Ul 
l. 
Figure 12. ·Total plasma bilirubin levels after partial 
hepatectomy. Group values are averages of single 
determinations from each animal. 
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TABLE 10 
Total Plasma Bilirubin 
24 hr 48 hr 96 hr 
3.42 3.66 1.94 
0.77 0.36 0.08 
4 3 4 
4.7 6.25 2.29 
2.89 3.43 0.38 
5 5 4 
2.13 2.43 2.35 
0.42 1 0.09 
4 4 3 
l. 02 0.22 
0.88 0 
2 2 
144 hr 
2.95 
0.04 
2 
0.49 
0.07 
2 
2.4 
0.01 
3 
192 hr 
2.58 
0.27 
2 
2.54 
0.37 
2 
1.96 
0.34 
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Figure 13. Plasma ammonia concentrations. Group values are 
averages of single determinations from each 
animal. 
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TABLE 11 
Plasma GPT Activity 
Group 0 hr 24 hr 48 hr 
Frearnine III avg. 31.56 108.51* 51.82* 
s.d. 2.33 24.19 16.12 
n 4 4 5 
Balanced Avg. 27.3 116.54** 64.18 
s.d. 0.84 16.36 16.49 
n 4 4 4 
Saline avg. 29.3 181.18 102.02 
s.d. 2.49 13.13 7.54 
n 3 2 2 
Sham avg. 79.9 68.55 
s.d. 1. 89 2.36 
n 2 2 
* p < 0.1 ** p < 0.05 
.Ul.l 
96 hr 144 hr 192 hr 
11.35*** -2.36 7.83 
4.05 2.36 7.25 
4 1 2 
28.21 15.13* 8.75 
3.87 10.87 5.91 
3 2 2 
41.76 36.19 34.04 
12.44 1. 05 2.05 
1 3 1 
*** p < 0.025 
,[,_ 
-...] 
1-' 
Figure 14. Plasma glutamic pyruvic tranaminase activity 
after partial hepatectomy. Group values are 
averages of single determinations from each 
animal. 
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Figure 15. Cannula Patency 
Patency is used here as the ability to 
obtain blood samples from an animal. 
Percentages in this graph are bases on 
the total number of animals starting in 
each group. Thus patency decreased with 
cannula occlusion and/or animal death. 
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